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Abstracts 
NC-02. NEURAL STEM/PROGENITOR CELLS AND GLIOMA 
STEM-LIKE CELLS HAVE DIFFERENTIAL SENSITIVITY TO 
COMMONLY USED CHEMOTHERAPY DRUGS 
Xing Gong 1, Philip Schwartz 2, Mark Linskey 1, and Daniela A. Bota 1; 
1University of California, Irvine; 2Children's Hospital of Orange County 
OBJECTIVES: Glial tumors are often lethal, but the survivors have mul­
tiple cognitive impairments. New data suggest that glioma stem-like cells 
(GSCs) and neural stem/progenitor cells (NSCs) share common origins. 
GSCs drive tumor proliferation and appear to be resistant to classical che­
motherapy, while the effects of chemotherapy on NSCs have not been well 
studied. As the role of NSCs in learning and memory is increasingly recog­
nized, we need to identify drugs that reduce neurotoxicity but are still effec­
tive against glial tumors. METHODS: We treated three human NSC cultures 
and multiple low- and high-grade GSC cultures with the commonly used 
agents temozolomide (TMZ) and cisplatin (CIS), and with two newer, 
promising drugs: the proteasome inhibitor bortezomib (BTZ) and the 
epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (ERL). 
We measured cell survival, proliferation, cell-death induction, and 
drug-resistance markers. RESULTS: TMZ decreased NSC viability, while 
minimally affecting GSCs. TMZ induced NSC death, which was partially 
compensated for by an increase in proliferation. CIS had similar effects. 
The NSC's sensitivity to TMZ and CIS correlated with a low expression of 
the multidrug resistance gene ABCG2, but not with MGMT or MSHl/ 
MLH2. Conversely, BTZ caused an 80% decrease in GSCs, while minimally 
affecting NSCs. GSCs had lower proteasome mRNA levels and activity and 
higher caspase-3 induction after BTZ treatment. ERL treatment also 
decreased GSC numbers but not NSC viability, which correlated with 
lower EGFR expression in NSCs than that in GSCs. CONCLUSIONS: 
Newer chemotherapy agents ERL and BTZ are effective against GSCs yet 
produce minimal effects on NSCs, while the older drugs TMZ and CIS are 
more toxic for NSCs than they are for GSCs. Since the ultimate goal of che­
motherapy is the eradication of tumors (mediated by GSCs) while maintain­
ing patient cognition (mediated by NSCs), the use of more selective drugs is 
clearly warranted. 
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